Log In
Print
BCIQ
Print
Print this Print this
 

Invega Sustenna paliperidone palmitate

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionIntramuscular injection of paliperidone, a metabolite of risperidone, given once every 3 months
Molecular Target Monoamine receptors
Mechanism of ActionMonoaminergic receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationSchizophrenia
Indication DetailsTreat schizophrenia
Regulatory Designation

U.S. - Priority Review (Treat schizophrenia)

Partner

Alkermes plc


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today